Post-market Clinical Follow-up Study of NEMOST V2
Post-market Clinical Follow-up Study of NEMOST V2 Growing Domino
EUROS
140 participants
Dec 19, 2025
INTERVENTIONAL
Conditions
Summary
The NEMOST spinal implant is a growth domino intended for the surgical treatment of progressive scoliosis in children. As part of post-market surveillance, EUROS is conducting a retrospective and prospective study to collect clinical and radiological data on the NEMOST growth domino. Retrospective and prospective multicenter post-market surveillance clinical study. This study is interventional, non-randomized, and uncontrolled. The primary objective of this clinical study is to monitor complications related to the NEMOST growth domino during a 5-year postoperative follow-up in patients treated for progressive scoliosis in children. The secondary objective of this clinical study is to monitor the performance of the NEMOST growth domino during a 5-year postoperative follow-up in patients treated for progressive scoliosis in children. The study will include 140 patients.
Eligibility
Inclusion Criteria3
- Idiopathic, congenital, neuromuscular, or syndromic scoliosis : Progressive spinal deformity not managed by orthopedic treatment, and requiring primary surgical intervention.
- The patient, as well as their parents or legal guardians, are informed of the participation in the study.
- Patients aged from 5 to 17 yeas old, excepted the one who still have a potential for growth
Exclusion Criteria6
- signs of local inflammation;
- acute or chronic, local or systemic infections ;
- non-reducible scoliosis ;
- pathological obesity ;
- allergy or intolerance to implanted materials;
- insufficiency or absence of tissue coverage. The NEMOST implant should not be used in a spine that has already been instrumented or fused.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
The NEMOST spinal implant is a growth domino intended for the surgical treatment of progressive scoliosis in children.
Locations(5)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07403084